Replies to post #126 on Viatris (VTRS)

[DewDiligence]

MYL did not acquire Mapi Pharma—they acquired the rights to one of Mapi’s investigational drugs (a long-acting formulation of Copaxone):

https://www.prnewswire.com/news-releases/mylan-to-acquire-the-global-marketing-rights-to-a-once-monthly-glatiramer-acetate-product-through-an-investment-and-partnership-with-israeli-company-mapi-pharma-300626931.html